首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >The comparative effects of Itopride and Levosulpiride orally used in patients suffering from Non-ulcer dyspepsia
【24h】

The comparative effects of Itopride and Levosulpiride orally used in patients suffering from Non-ulcer dyspepsia

机译:口服伊托必利和左硫舒必利在非溃疡性消化不良患者中的比较效果

获取原文
           

摘要

Background: Itopride and Levosulpiride both comes under the group of Prokinetic drugs. These drugs are used for the treatment of non-ulcer dyspepsia, heart burn, nausea and vomiting. Both drugs act on dopaminergic D2 receptor as antagonist and increases the concentration of acetylcholine so that gastric peristalsis will be increase and that time pressure at lower oesophageal sphincter will be increase thus gastric motility increases and there will be good gastro-duodenal co-ordination. Method: This study has to conduct on patients with complains of non-ulcer dyspepsia attended Medical outdoor and department of pharmacology of SKMCH Muzaffarpur, Bihar, India. The total 60 patients have to include in the study, which have to randomly divide in two groups. Group A (itopride) comprising of 30 patients and Group B (Levosulpiride) comprising of 30 patients. Patients have to randomly allocate to receive one tablet of itopride hydrochloride, 50 mg three times daily before meal and one tablet Levosulpiride of 75 mg three times daily before meal. Authors have to enroll the patients at the interval of two weeks and continue it upto 3 months. Results: Study did not found any remarkable change in biochemistry profile. Only QT prolongation changes were found in two patients, but no serious cardiac toxicity was observed with patient receiving Levosulpiride. Neither QT prolongation nor serious cardiac toxicity was observed with itopride hydrochloride therapy. Conclusions: In present study, efficacy of Itopride was comparable to Levosulpiride in relieving the symptoms of non-ulcer dyspepsia. Both the drugs were clinically and biochemically well tolerated. QT prolongation changes were found in two patients, but no serious cardiac toxicity was observed with patient receiving Levosulpiride. Itopride does not show cardiac toxicity and any changes in ECG.
机译:背景:依托必利和左舒必利都属于促动力药。这些药物用于治疗非溃疡性消化不良,烧心,恶心和呕吐。两种药物均以多巴胺能D2受体为拮抗剂起作用,并增加乙酰胆碱的浓度,从而增加胃蠕动,并增加下食道括约肌的时间压力,从而增加胃动力,并具有良好的胃-十二指肠协调性。方法:该研究必须针对印度比哈尔邦SKMCH Muzaffarpur参加过医疗户外和药理学的非溃疡性消化不良患者进行。总共60名患者必须纳入研究,这些患者必须随机分为两组。包括30名患者的A组(依托必利)和包括30名患者的B组(左舒必利)。病人必须随机分配,以在餐前每天服用3次,每次50毫克的盐酸伊托必利和餐前3次,每天服用3次的75毫克左磺舒必利的随机分配。作者必须在两周的间隔内招募患者,并将其延长至3个月。结果:研究未发现生物化学特征有任何显着变化。两名患者仅发现QT延长改变,但接受左苏必利的患者未观察到严重的心脏毒性。盐酸伊托必利治疗未观察到QT延长或严重的心脏毒性。结论:在本研究中,伊托必利在缓解非溃疡性消化不良症状方面的功效与左舒必利相当。两种药物在临床和生化上均耐受良好。在两名患者中发现了QT延长的变化,但是在接受左舒必利治疗的患者中未观察到严重的心脏毒性。依托必利不显示心脏毒性和心电图改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号